FY2025 EPS Estimate for Editas Medicine Reduced by Analyst

Editas Medicine, Inc. (NASDAQ:EDIT) – Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Editas Medicine in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.06) for the year, down from their prior forecast of ($1.05). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for Editas Medicine’s FY2026 earnings at ($0.65) EPS.

A number of other analysts have also issued reports on EDIT. Bank of America lowered Editas Medicine from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $13.00 to $1.00 in a research note on Monday, November 25th. Raymond James lowered shares of Editas Medicine from an “outperform” rating to a “market perform” rating in a research report on Monday, November 4th. Stifel Nicolaus lowered shares of Editas Medicine from a “buy” rating to a “hold” rating and decreased their price target for the company from $11.00 to $3.00 in a report on Friday, December 13th. Robert W. Baird dropped their price objective on Editas Medicine from $10.00 to $8.00 and set an “outperform” rating for the company in a report on Friday, December 13th. Finally, JPMorgan Chase & Co. cut Editas Medicine from a “neutral” rating to an “underweight” rating in a report on Monday, December 16th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Editas Medicine Price Performance

Shares of NASDAQ EDIT opened at $1.38 on Friday. Editas Medicine has a 12 month low of $1.12 and a 12 month high of $11.58. The company has a 50-day simple moving average of $1.64 and a 200-day simple moving average of $3.10. The company has a market cap of $113.92 million, a PE ratio of -0.54 and a beta of 1.95.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Monday, November 4th. The company reported ($0.75) earnings per share for the quarter, meeting the consensus estimate of ($0.75). The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $3.93 million. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The firm’s revenue for the quarter was down 98.9% on a year-over-year basis. During the same period last year, the firm posted ($0.55) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Signaturefd LLC lifted its holdings in Editas Medicine by 494.8% in the 3rd quarter. Signaturefd LLC now owns 9,326 shares of the company’s stock worth $32,000 after buying an additional 7,758 shares in the last quarter. Ballentine Partners LLC acquired a new position in shares of Editas Medicine in the third quarter worth about $36,000. Thrive Wealth Management LLC purchased a new position in Editas Medicine in the fourth quarter valued at about $36,000. Arcadia Investment Management Corp MI acquired a new stake in Editas Medicine during the 3rd quarter valued at approximately $39,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Editas Medicine during the 3rd quarter worth approximately $47,000. 71.90% of the stock is currently owned by hedge funds and other institutional investors.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.